Silo Pharma, Inc. (Nasdaq: SILO), a biopharmaceutical company focused on developing innovative therapeutics, has recently filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset, SPC-15. This filing underscores the company’s dedication to advancing treatments for stress-induced psychiatric disorders, particularly post-traumatic stress disorder (PTSD).
SPC-15 is an intranasal treatment designed as a serotonin 5-HT4 receptor agonist, targeting stress-induced psychiatric conditions such as PTSD and anxiety. The provisional patent specifically covers the chronic, combinatorial targeting of N-methyl-D-aspartate receptors (NMDARs) and serotonin type IV receptors (5-HT4Rs). This dual-target approach aims to enhance behavioral outcomes against stress-related perseverative behavior and hyponeophagia, which are common in patients suffering from PTSD.
The patent filing adds to Silo Pharma’s expanding portfolio of intellectual property related to the SPC-15 technology, which was initially licensed through a collaboration with Columbia University. This exclusive agreement allows Silo to develop, manufacture, and commercialize SPC-15 on a global scale.
Eric Weisblum, CEO of Silo Pharma, emphasized the significance of intellectual property in the company’s growth strategy. He stated, “Our intellectual property strategy continues to be a cornerstone of our growth. This latest provisional patent application reinforces our strong IP protection for SPC-15 and further positions us to deliver innovative therapies for patients with PTSD and other stress-induced disorders.” Such statements reflect Silo’s commitment to building a robust foundation for its therapeutic developments.
Silo Pharma is not only focusing on securing patents but also advancing its research efforts. The company collaborates closely with Columbia University to conduct preclinical studies on SPC-15. These studies aim to explore the efficacy of SPC-15 in treating severe stress-related psychiatric conditions. Given the promising results from preclinical trials demonstrating the effectiveness of combining 5-HT4R agonism with NMDAR antagonism, Silo is optimistic about the potential therapeutic benefits of this dual-action approach.
The company is also preparing for an Investigational New Drug (IND) application submission, which could facilitate accelerated approval through the FDA’s streamlined 505(b)(2) regulatory pathway. This pathway is particularly advantageous for drugs that can leverage existing data from similar products, potentially shortening the time frame for bringing SPC-15 to market.
Silo Pharma’s focus extends beyond PTSD treatment; its portfolio includes other innovative programs targeting chronic pain conditions and central nervous system diseases. As Silo Pharma advances its development initiatives, it aims to provide effective solutions for patients suffering from debilitating conditions like PTSD and anxiety. The successful execution of its intellectual property strategy coupled with ongoing research could pave the way for significant advancements in therapeutic options available in the market. Silo Pharma’s recent provisional patent filing marks a critical step in its mission to develop novel treatments for stress-induced disorders.